CXCL8 and neoplasm: Our studies also suggest that monitoring the status of phospho-ERK1/2 and phospho-FAK S910 in tumor biopsies can be a good indicator for adverse effects, and that blood levels of IL8 and LIF may serve as markers, because normal cells were either inhibited or not-responsive to the drug.